Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 9/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 6/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 6/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 4/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034687 | 0.91 | HDAC6 (0.83) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL3033469 | 0.90 | HDAC6 (0.81) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL14260700 | 0.89 | HDAC1 (0.80) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL28918342 | 0.88 | HDAC1 (0.79) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL14894197 | 0.88 | NR1H4 (0.85) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL12588095 | 0.87 | HDAC1 (0.77) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL3028724 | 0.87 | HDAC6 (0.76) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL7322242 | 0.87 | NR1H4 (1.00) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL2412199 | 0.86 | HDAC1 (0.75) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL4569169 | 0.86 | HDAC1 (0.75) | HDAC6HDAC1HDAC8HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150056191-A1 | IGF1 BIOMARKER FOR IGF1R INHIBITOR THERAPY | MERCK SHARP & DOHME CORP. | 2015-02-26 | — | — | US | disclosed |
| US-20140079665-A1 | THERAPEUTIC ANTI-IGF1R COMBINATIONS | MERCK SHARP & DOHME CORP. | 2014-03-20 | — | — | US | disclosed |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2405270-B1 | IGFBP2-Biomarker | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8470297-B1 | FDG-pet evaluation of Ewing's sarcoma sensitivity | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2013057186-A1 | PHOTOLABILE LINKER FOR THE SYNTHESIS OF HYDROXAMIC ACIDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012158657-A1 | THERAPEUTIC ANTI-IGF1R COMBINATIONS | MERCK SHARP & DOHME CORP. (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2405270-A1 | IGFBP2-Biomarker | Schering Corporation (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011057064-A1 | IGF1R INHIBITOR BASED TREATMENT OF PROSTATE CANCER | LONG BRIAN (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| WO-2010124009-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | SCHERING CORPORATION (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2009055343-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009005673-A1 | ANTI-IGF1R | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080112888-A1 | IGFBP2 BIOMARKER | SCHERING CORPORATION | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | HDAC6 1580/4885HDAC1 1207/4885HDAC8 1250/4885 |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | IGF1R, IRS1, EWSR1 | HDAC6 3567/4885HDAC1 2097/4885HDAC8 2306/4885 |
| US-20080112888-A1 | IGFBP2 BIOMARKER | IGFBP2, IGFBP1, IGFBP5 | HDAC6 1580/4885HDAC1 1207/4885HDAC8 1250/4885 |
| US-20150056191-A1 | IGF1 BIOMARKER FOR IGF1R INHIBITOR THERAPY | IGF1R, IGFBP1, IGF2BP2 | HDAC6 3085/4885HDAC1 1120/4885HDAC8 1778/4885 |
| US-20140079665-A1 | THERAPEUTIC ANTI-IGF1R COMBINATIONS | IGF1R, IGFBP1, IGFBP3 | HDAC6 653/4885HDAC1 849/4885HDAC8 1805/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | HDAC6 84/4885HDAC1 89/4885HDAC8 180/4885 |
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | HDAC6 130/4885HDAC1 699/4885HDAC8 436/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | HDAC6 1868/4885HDAC1 2006/4885HDAC8 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.